Evidence map›Paper›PMID 35429328›Full record

ArticleInternational journal of hematology2022

Comparison of the impact of two post-remission therapy regimens on cardiac events in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.

Jin Hayakawa, Hideki Nakasone, Daisuke Minakata, Shin-Ichiro Fujiwara, Ayumi Gomyo, Yu Akahoshi, Yusuke Komiya, Naonori Harada, Tomotaka Ugai, Kazuaki Kameda and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 1 institution in 1 country.

Jin HayakawaDivision of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma Town, Omiya Ward, Saitama City, Saitama, 330-8503, Japan.
Hideki NakasoneDivision of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma Town, Omiya Ward, Saitama City, Saitama, 330-8503, Japan.
Daisuke MinakataDivision of Hematology, Department of Medicine, Jichi Medical University Hospital, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0431, Japan.
Shin-Ichiro FujiwaraDivision of Hematology, Department of Medicine, Jichi Medical University Hospital, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0431, Japan.
Ayumi GomyoDivision of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma Town, Omiya Ward, Saitama City, Saitama, 330-8503, Japan.
Yu AkahoshiDivision of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma Town, Omiya Ward, Saitama City, Saitama, 330-8503, Japan.
Yusuke KomiyaDivision of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma Town, Omiya Ward, Saitama City, Saitama, 330-8503, Japan.
Naonori HaradaDivision of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma Town, Omiya Ward, Saitama City, Saitama, 330-8503, Japan.
Tomotaka UgaiDivision of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma Town, Omiya Ward, Saitama City, Saitama, 330-8503, Japan.
Kazuaki KamedaDivision of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma Town, Omiya Ward, Saitama City, Saitama, 330-8503, Japan.
Hidenori WadaDivision of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma Town, Omiya Ward, Saitama City, Saitama, 330-8503, Japan.
Yuko IshiharaDivision of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma Town, Omiya Ward, Saitama City, Saitama, 330-8503, Japan.
Koji KawamuraDivision of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma Town, Omiya Ward, Saitama City, Saitama, 330-8503, Japan.
Kana SakamotoDivision of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma Town, Omiya Ward, Saitama City, Saitama, 330-8503, Japan.
Miki SatoDivision of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma Town, Omiya Ward, Saitama City, Saitama, 330-8503, Japan.
Kiriko Terasako-SaitoDivision of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma Town, Omiya Ward, Saitama City, Saitama, 330-8503, Japan.
Misato KikuchiDivision of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma Town, Omiya Ward, Saitama City, Saitama, 330-8503, Japan.
Shun-Ichi KimuraDivision of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma Town, Omiya Ward, Saitama City, Saitama, 330-8503, Japan.
Junya KandaDivision of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma Town, Omiya Ward, Saitama City, Saitama, 330-8503, Japan.
Shinichi KakoDivision of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma Town, Omiya Ward, Saitama City, Saitama, 330-8503, Japan.
Yoshinobu KandaDivision of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma Town, Omiya Ward, Saitama City, Saitama, 330-8503, Japan. ycanda-tky@umin.ac.jp.ORCID http://orcid.org/0000-0002-4866-9307
Jichi Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-dose cytarabine (HD-AraC) or anthracycline-containing chemotherapies are used as post-remission therapy for acute myeloid leukemia (AML) patients. However, it remains unclear which regimen would be better as post-remission therapy before allogeneic hematopoietic stem cell transplantation (allo-HSCT). Thus, we compared the incidence of cardiac events and event-free survival (EFS) after allo-HSCT at two Japanese hospitals between HD-AraC and anthracycline-containing post-remission therapy to clarify the safety of post-remission therapy. Of a total of 132 patients, 68 received HD-AraC (HD-AraC group) and 64 received anthracycline-containing chemotherapy (ANT group). HD-AraC was preferentially selected for core-binding factor AML patients (p = 0.008). The median cumulative anthracycline dose was 115.2 mg/m

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteAnthracyclinesCytarabineHumansRemission InductionAnthracyclinesCytarabineAcute myeloid leukemiaAnthracyclinesBone marrow transplantationCardiotoxicityChemotherapy

Identifiers

PMID35429328
OpenAlexW4223981533

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.